From: Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis
Grade 1A | Cutaneous rash, flushing, generalised pruritus | 5 (17.9%) |
---|---|---|
Grade 1B | 1A plus, back pain and or HTN | 2 (7.1%) |
Grade 2 | Urticaria, nausea/vomiting, throat tightness, Asymptomatic bronchospasm, chest tightness | 3 (10.7%) |
Grade 3 | Symptomatic bronchospasm, dysponea, hypoxia, wheeze | 7 (25%) |
Grade 4 | Anaphylaxis, hypotension | 0 |
Grade 5 | Death | 1 (3.6%) |
Unclassified | due to lack of information available to stratify severity | 4 (14.3%) |
Delayed | adverse event occurred after 48 h of infusion | 6 (21.4%) |